• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 5. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119

Introduction to 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline (CAS No. 881310-87-8)

2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline (CAS No. 881310-87-8) is a synthetic compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential therapeutic applications. This compound belongs to the quinazoline class, which is known for its diverse biological activities, including antitumor, anti-inflammatory, and antiviral properties.

The chemical structure of 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline is characterized by a quinazoline core substituted with a 4-bromophenyl group at the 2-position, a chlorine atom at the 4-position, and a fluorine atom at the 6-position. These substitutions contribute to the compound's high chemical stability and its ability to interact with various biological targets. The bromine and chlorine atoms enhance the lipophilicity of the molecule, facilitating its cellular uptake and distribution.

Recent studies have focused on the pharmacological properties of 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline. One notable area of research is its potential as an anticancer agent. In vitro studies have shown that this compound exhibits significant cytotoxic activity against various cancer cell lines, including breast cancer, lung cancer, and colon cancer cells. The mechanism of action is believed to involve the inhibition of key signaling pathways involved in cell proliferation and survival, such as the PI3K/AKT and MAPK/ERK pathways.

In addition to its anticancer properties, 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline has also been investigated for its anti-inflammatory effects. Inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease, are characterized by chronic inflammation and tissue damage. Preclinical studies have demonstrated that this compound can effectively reduce inflammation by inhibiting the production of pro-inflammatory cytokines and chemokines. This makes it a promising candidate for the development of novel anti-inflammatory drugs.

The pharmacokinetic profile of 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline has been extensively studied to understand its behavior in biological systems. Research has shown that it exhibits good oral bioavailability and a favorable half-life, making it suitable for chronic administration. However, further studies are needed to optimize its pharmacokinetic properties and minimize potential side effects.

In terms of safety, preclinical toxicity studies have indicated that 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline is generally well-tolerated at therapeutic doses. However, like many other small molecules with potent biological activities, it may exhibit off-target effects at higher concentrations. Therefore, careful dose-ranging studies are essential to determine the optimal therapeutic window.

The synthesis of 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline has been optimized using various synthetic routes to improve yield and purity. One common approach involves the condensation of 2-amino-5-bromoanisole with 1-chloro-3-fluorobenzene in the presence of a suitable catalyst. This method has been shown to produce high yields of the desired product with minimal side reactions.

In conclusion, 2-(4-Bromophenyl)-4-chloro-6-fluoroquinazoline (CAS No. 881310-87-8) is a promising compound with a wide range of potential applications in medicinal chemistry. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for further development as a therapeutic agent. Ongoing research aims to elucidate its full potential and optimize its use in clinical settings.

• 885277-41-8(4,7-Dichloro-2-(4-Fluoro-Phenyl)-Quinazoline)
• 885277-09-8(4-Chloro-6-fluoro-2-phenylquinazoline)
• 885277-32-7(4-Chloro-6-fluoro-2-(4-fluorophenyl)quinazoline)
• 885277-38-3(Quinazoline,4-chloro-2-(4-fluorophenyl)-6-methyl-)
• 405933-98-4(2-(4-Bromophenyl)-4,6-dichloroquinazoline)
• 412923-42-3(6-Bromo-4-chloro-2-phenylquinazoline)
• 113242-33-4(4-chloro-2-(4-fluorophenyl)quinazoline)
• 885277-10-1(Quinazoline,4-chloro-7-fluoro-2-phenyl-)
• 885277-35-0(6-Bromo-4-chloro-2-(4-fluorophenyl)quinazoline)
• 83800-98-0(2-(4-bromophenyl)-4-chloroquinazoline)